Clinical trials · New York
Advanced Solid Tumor clinical trials in New York
We’re tracking 233 recruiting advanced solid tumor studies with a site in New York — including Phase 1, Phase 1/Phase 2 and Phase 2 studies, each written for real people, not researchers.
Recruiting studies in New York
- NCT05098132RecruitingPhase 1/Phase 2
STK-012 drug for advanced lung cancer and other tumors
This trial tests STK-012 (alone and with other treatments) in people with advanced cancers, especially non-small cell lung cancer. It may help by activating the immune system to recognize and fight the tumor.
Lake Success, New YorkAges 18 years+ - NCT06060613RecruitingPhase 1/Phase 2
OBX-115 cell therapy for advanced melanoma or lung cancer
This trial tests an experimental cell therapy called OBX-115 for people with advanced melanoma or non-small cell lung cancer that has not responded to standard treatments. The therapy uses your own immune cells to fight the cancer. The study aims to see if it is safe and effective.
New York, New YorkAges 18 years+ - NCT07612176RecruitingPhase 1
Testing NEOK001 drug for advanced solid tumors
This study tests a new cancer drug called NEOK001 that targets two proteins (B7-H3 and ROR1) found on certain tumor cells. The drug combines a cancer-fighting molecule with a toxic payload to kill cancer cells while sparing healthy tissue.
New York, New YorkAges 18 years+ - NCT07638371RecruitingPhase 1
MSK-TCR5 Cell Therapy for RAS G12D Solid Tumors
This study tests a new type of cell therapy called MSK-TCR5, designed to fight solid cancers (like pancreatic, lung, or colon cancer) that have a specific RAS G12D mutation. The therapy uses your own immune cells trained to recognize and attack cancer cells with this mutation.
Commack, New YorkAges 18 years+ - NCT07196644RecruitingPhase 2
A study of a new drug for certain cancers with a specific gene change
This trial tests a drug called telisotuzumab adizutecan for people whose cancer has a specific genetic change called MET amplification. It may help when standard treatments are no longer working.
New York, New YorkAges 12 years+ - NCT07436728RecruitingPhase 1/Phase 2
Study of TAK-505 for adults with solid tumors
This trial tests TAK-505, an experimental drug, for people with advanced solid tumors including lung, colorectal, stomach, or head and neck cancers. It aims to see if the drug can help when standard treatments are no longer working or aren't suitable.
New York, New YorkAges 18 years+ - NCT05669430RecruitingPhase 1/Phase 2
Testing an anti-cancer drug alone and with pembrolizumab
This early-phase study tests GV20-0251 (an anti-cancer treatment) by itself and combined with pembrolizumab, to see how well it works and how safe it is. It is for adults with advanced solid tumors that have grown despite standard treatments, or where standard treatments aren’t an option.
New York, New YorkAges 18 years+ - NCT06218914RecruitingPhase 1
Study of a new treatment for KRAS G12D cancers
This trial tests a new type of cell therapy (called TCR-T) that targets a specific genetic change (KRAS G12D) in advanced solid tumors that have stopped responding to standard treatments. It may be an option if your cancer has this mutation and you have a specific tissue type (HLA).
New York, New YorkAges 18 years+ - NCT02693535RecruitingPhase 2
Match FDA cancer drugs to a tumor gene change
This trial tests FDA-approved cancer medicines in people with advanced cancer whose tumor has a specific gene or protein abnormality. It tries to see whether targeting that tumor “fingerprint” can help when standard treatments no longer work.
New Hyde Park, New YorkAges 12 years+ - NCT06998407RecruitingPhase 1/Phase 2
Study of AVZO-023 for advanced solid tumors
This trial tests a new drug, AVZO-023, alone or with other treatments, for people with advanced solid tumors that have not responded to standard therapy. The goal is to see if it can shrink tumors or slow their growth.
New York, New YorkAges 18 years+ - NCT06427941RecruitingPhase 1
Study of BGB-B2033 drug for advanced solid tumors
This trial tests a new drug, BGB-B2033, alone or with other treatments, for people with advanced liver, stomach, lung, or germ cell cancers that have not responded to standard therapy. The goal is to see if the drug is safe and works against these tumors.
New York, New YorkAges 18 years+ - NCT06276491RecruitingPhase 1
XmAb541 for advanced solid tumors
This phase 1 trial tests a new drug, XmAb541, for people with advanced solid tumors (ovarian, endometrial, or germ cell tumors) that have not responded to previous treatments. The trial focuses on people whose tumors have a specific protein called CLDN6 and aims to find a safe and effective dose.
New York, New YorkAges 15 years+ - NCT07095868RecruitingPhase 1/Phase 2
Study of EVM14 for advanced solid tumors
This trial tests a new drug called EVM14, alone or with other treatments, for people with advanced solid tumors that can't be removed by surgery or have spread. It aims to see if the drug is safe and helps shrink or control the cancer.
New York, New YorkAges 18 years+ - NCT05735080RecruitingPhase 1/Phase 2
INX-315 for advanced cancers with a specific gene change
This trial studies an experimental medicine (INX-315) given in an “open-label” way to people with advanced cancer that has not responded to prior treatment. It mainly looks at safety and side effects first, and also checks how well it works in cancers with a specific gene amplification.
Buffalo, New YorkAges 18 years+ - NCT04890613RecruitingPhase 1
CX-5461 for cancers with BRCA or HRD gene changes
This Phase 1 trial tests CX-5461, a new cancer medicine, in people with certain solid tumors that have BRCA1/2 or related “HRD” gene mutations. The goal is to find out how the drug works, what dose is tolerable, and whether it can help shrink tumors.
New York, New YorkAges 18 years+ - NCT05355701RecruitingPhase 1
Testing a new drug for advanced cancers with BRAF changes
This Phase 1 trial studies PF-07799933, a new medicine, in people whose advanced solid tumors have specific BRAF genetic changes. It may help if your cancer has continued to grow after standard treatments, and there may be specific options depending on your cancer type and past therapies.
New York, New YorkAges 16 years+ - NCT07164313RecruitingPhase 1
ZW251 for advanced solid tumors
This trial is testing a new drug called ZW251 for people with advanced liver cancer (hepatocellular carcinoma), non-small cell lung cancer, or germ cell tumors that have spread or cannot be removed by surgery. It aims to see if the drug is safe and effective.
New York, New YorkAges 18 years+ - NCT06413680RecruitingPhase 1/Phase 2
Study of REGN10597 with or without cemiplimab for advanced solid tumors
This study tests a new drug called REGN10597, either alone or with cemiplimab, for people with advanced solid tumors (like melanoma or kidney cancer) that have not responded to standard treatments. The goal is to see if the combination can shrink tumors or slow their growth.
Lake Success, New YorkAges 18 years+ - NCT05985655RecruitingPhase 1/Phase 2
Study of GTAEXS617 for advanced solid tumors
This trial tests a new drug called GTAEXS617 for adults with certain advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and effective.
New York, New YorkAges 18 years+ - NCT07593092RecruitingPhase 1
Testing new cancer immunotherapy for advanced ovarian cancer
This study tests two new experimental drugs (XmAb541 and XmAb808) designed to fight advanced ovarian cancer by activating your immune system. You'll be closely monitored to see how safe the drugs are and how your body tolerates them.
Lake Success, New YorkAges 18 years+ - NCT07277413RecruitingPhase 1
Study of IDE892 for advanced solid tumors with MTAP deletion
This study tests a new drug called IDE892, alone or in combination, for people with advanced solid tumors that have a specific genetic change (MTAP deletion). The goal is to see if the drug is safe and whether it can shrink tumors.
New York, New YorkAges 18 years+ - NCT07287917RecruitingPhase 1/Phase 2
Testing a new drug combo for advanced breast cancer or melanoma
This trial tests a new combination of drugs (AMXT 1501, DFMO, and standard therapies) for people with advanced solid tumors, specifically breast cancer (ER+ HER2-) or melanoma that has progressed after other treatments. The goal is to see if this combination can help shrink tumors or slow their growth.
Lake Success, New YorkAges 18 years+ - NCT04429542RecruitingPhase 1
Test of an EGFR-targeting drug for advanced solid cancers
This Phase 1 study tests the safety of BCA101 (an EGFR-targeting treatment) alone or combined with pembrolizumab. It may help people with certain EGFR-driven advanced cancers, depending on the tumor type, prior treatments, and required biopsy testing.
New York, New YorkAges 18 years+ - NCT04895709RecruitingPhase 1/Phase 2
Testing a new cancer drug for advanced solid tumors
This early-phase trial tests how well a new drug (BMS-986340) works alone and combined with other treatments in people with advanced solid tumors that have progressed despite standard care. It also studies tumor samples to look for biomarkers that may predict who benefits.
New York, New YorkAges 18 years+
Advanced Solid Tumor trials by city in New York
Where these studies are running in New York
Institutions with a site for the recruiting advanced solid tumor studies listed above.
- Memorial Sloan Kettering Cancer Center · 12 studies
- Columbia University Irving Medical Center · 2 studies
- Icahn School of Medicine at Mount Sinai · 2 studies
- Northwell Health · 2 studies
- NYU Langone Health · 2 studies
- Avenzo Therapeutics Recruiting Site
- Columbia University Herbert Irving Comprehensive Cancer Center
- Local Institution - 0002
What taking part in a advanced solid tumor study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Advanced Solid Tumor trials in other states
Common questions
- Are there advanced solid tumor clinical trials in New York?
- Yes. We're currently tracking 233 recruiting advanced solid tumor studies with a site in New York, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a advanced solid tumor study in New York?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in New York to take part?
- Not necessarily. These studies have a site in New York, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a advanced solid tumor trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New advanced solid tumor studies open in New York regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.